Bioxyne Ltd
Research Bioxyne Ltd (BXN) on Bullrun: market cap AUD 217.33M, P/E 23.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBXN
- ExchangeAU
- CountryAustralia
- SectorConsumer Defensive
- IndustryPackaged Foods
- CurrencyAUD
- Market capAUD 217.33M
- P/E23.8
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 217.33M; P/E is 23.8.
Peer valuation comparison
Latest P/E is 23.81x versus a Consumer Defensive sector median of 17.41x (36.8% above).
Latest P/E is 23.81x versus a Australia median of 16.97x (40.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | 0.02 | n/a | n/a | n/a |
| FY2024 | AUD 9.33M | -AUD 13.33M | -AUD 4.09M | 36.4% | n/a | AUD 1.03M | AUD 673.72K | AUD 3.61M |
| FY2023 | AUD 5.16M | -AUD 1.96M | -AUD 1.19M | 36.8% | 0 | AUD 3.85M | n/a | AUD 15.14M |
| FY2022 | AUD 2.42M | -AUD 236.51K | AUD 429.23K | 53.3% | 0 | AUD 2.17M | n/a | AUD 1.89M |
| FY2021 | AUD 2.11M | -AUD 425.73K | AUD 53.13K | 51.2% | 0 | AUD 1.60M | n/a | AUD 1.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 217.33M | 23.8 | n/a | n/a |
About Bioxyne Ltd
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments.
Related stock research
Other Consumer Defensive stocks
Frequently asked questions
What is Bioxyne Ltd's market cap?
Bioxyne Ltd's market capitalization is AUD 217.33M.
What is Bioxyne Ltd's P/E ratio?
Bioxyne Ltd's price-to-earnings (P/E) ratio is 23.8.
What does Bioxyne Ltd do?
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments.